The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Official Title: An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Study ID: NCT01347645
Brief Summary: The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects. The purpose of the Phase II portion is to find out how safe the study drug is when taken at the highest dose in a larger group of subjects.
Detailed Description: This open-label, multicenter, randomized study will consist of a Phase Ib portion: a safety run-in period with 3 ascending doses of E7820; and a Phase II portion: a randomized 2-arm design. Approximately 95 patients with measurable, nonresectable locally advanced or metastatic colorectal adenocarcinoma, who have failed first-line chemotherapy, will be enrolled in the study (approximately 12 to 15 patients in the Phase Ib portion and 80 patients in the Phase II portion). Patients will only participate in either the Phase Ib or the Phase II portion of the study. Patients will receive up to a planned total of 12 cycles of study treatment unless there is occurrence of progressive disease, unacceptable toxicity, withdrawal of consent, withdrawal by the Investigator, lost to follow-up, or death, whichever occurs first. After 12 cycles, patients who demonstrate clinical benefit may continue single agent E7820 for long as clinical benefit is sustained and the treatment is well tolerated. If the treating physician does not feel comfortable discontinuing chemotherapy after 12 cycles, further chemotherapy may be considered following discussion with the medical monitor and sponsor.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, Birmingham, Alabama, United States
, West Palm Beach, Florida, United States
, Atlanta, Georgia, United States
, Ann Arbor, Michigan, United States
, Berkeley Heights, New Jersey, United States
, Bismarck, North Dakota, United States
, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
, La Rioja, LA Rioha, Argentina
, Rosario, Santa FE, Argentina
, Cordoba, , Argentina
, Coffs Harbour, New South Wales, Australia
, Concord, New South Wales, Australia
, Townsville, Queensland, Australia
, Elizabeth Vale, South Australia, Australia
, Kurralta Park, South Australia, Australia
, Woodville South, South Australia, Australia
, Carlton, Victoria, Australia
, Clayton, Victoria, Australia
, Epping, Victoria, Australia
, Frankston, Victoria, Australia
, Wodonga, Victoria, Australia
, Belo Horizonte, Minas Gerais, Brazil
, Novo Hamburgo, RIO Grande DO SUL, Brazil
, Passo Fundo, RIO Grande DO SUL, Brazil
, Port Alegre, RIO Grande DO SUL, Brazil
, Porto Alegre, RIO Grande DO SUL, Brazil
, Jau, SAO Paulo, Brazil
, Rio de Janeiro, , Brazil
, Arkhangelsk, , Russian Federation
, Chelyabinsk, , Russian Federation
, Moscow, , Russian Federation
, Sochi, , Russian Federation
, St. Petersburg, , Russian Federation
, St. Petersburg, , Russian Federation
, Dnipropetrovsk, , Ukraine
, Kharkiv, , Ukraine
, Kharkiv, , Ukraine
, Uzhgorod, , Ukraine
Name: Harish Dave
Affiliation: Quintiles, Inc.
Role: STUDY_DIRECTOR